Recent Trends in the Prevalence of Crohn’s Disease and Ulcerative Colitis in a Commercially Insured US Population

PurposeMost US inflammatory bowel disease (IBD) epidemiology studies conducted to date have sampled small, geographically restricted populations and have not examined time trends. The aim of our study was to determine the prevalence of Crohn’s disease (CD) and ulcerative colitis (UC) in a commercially insured US population and compare prevalences across sociodemographic characteristics and time.MethodsUsing claims data from approximately 12 million Americans, we performed three consecutive 2-year cross-sectional studies. Cases of CD and UC were identified using a previously described algorithm. Prevalence was estimated by dividing cases by individuals in the source population. Logistic regression was used to compare prevalences by region, age, and sex.ResultsIn 2009, the prevalences of CD and UC in children were 58 [95 % confidence interval (CI) 55–60] and 34 (95 % CI 32–36), respectively. In adults, the respective prevalences were 241 (95 % CI 238–245) and 263 (95 % CI 260–266). Data analysis revealed that IBD prevalences have slightly increased over time. Based on census data, an estimated 1,171,000 Americans have IBD (565,000 CD and 593,000 UC).ConclusionsAnalysis of the epidemiological data revealed an increasing burden of IBD in recent years, which may be used to inform policy.

[1]  J. Lewis,et al.  Incidence and Prevalence of Inflammatory Bowel Disease in a Northern California Managed Care Organization, 1996–2002 , 2008, The American Journal of Gastroenterology.

[2]  C. Porter,et al.  Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. , 2008, Gastroenterology.

[3]  D. Ollendorf,et al.  Infliximab Drug and Infusion Costs Among Patients With Crohn's Disease in a Commercially-Insured Setting , 2006, American journal of therapeutics.

[4]  Mieke Koehoorn,et al.  The Epidemiology of Inflammatory Bowel Disease in Canada: A Population-Based Study , 2006, The American Journal of Gastroenterology.

[5]  R. Platt,et al.  Estimation of the Period Prevalence of Inflammatory Bowel Disease Among Nine Health Plans Using Computerized Diagnoses and Outpatient Pharmacy Dispensings , 2007, Inflammatory bowel diseases.

[6]  R. Cohen,et al.  Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment , 2008, Inflammatory bowel diseases.

[7]  William J. Tremaine,et al.  Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000 , 2007, Inflammatory bowel diseases.

[8]  W. Mow,et al.  Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006. , 2010, The Journal of pediatrics.

[9]  R. Hoffmann,et al.  Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. , 2003, The Journal of pediatrics.

[10]  C. Porter,et al.  Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease , 2011, Inflammatory bowel diseases.

[11]  Ken Kleinman,et al.  The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  J. Mauskopf,et al.  Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. , 2001, Respiratory medicine.

[13]  A Wajda,et al.  Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. , 1999, American journal of epidemiology.